Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702049 | 1.00 | NFATC1 (0.36) | NFATC1GSK3BDYRK1APIK3CBMAPT | |
| SCHEMBL12670777 | 0.78 | NFATC1 (0.37) | NFATC1GSK3BDYRK1APIK3CBMAPT | |
| SCHEMBL21893814 | 0.76 | DHFR (0.44) | NFATC1GSK3BDYRK1APIK3CBMAPT | |
| SCHEMBL23937723 | 0.76 | NFATC1 (0.36) | NFATC1GSK3BDYRK1APIK3CBMAPT | |
| SCHEMBL29683313 | 0.76 | BRD9 (0.40) | MAPT | |
| SCHEMBL23912425 | 0.76 | — | — | |
| SCHEMBL22084634 | 0.74 | — | — | |
| SCHEMBL15164815 | 0.73 | RHEB (0.39) | NFATC1GSK3BDYRK1APIK3CBMAPT | |
| SCHEMBL14616909 | 0.73 | CCR4 (0.37) | NFATC1GSK3BDYRK1APIK3CBMAPT | |
| SCHEMBL16743120 | 0.73 | NQO2 (0.34) | NFATC1GSK3BDYRK1APIK3CBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4514794-A1 | FGFR2 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-117120439-A | FGFR3 inhibitor compounds | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023212535-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-11-02 | — | — | WO | disclosed |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NFATC1 3976/4885GSK3B 3553/4885DYRK1A 4538/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | NFATC1 3976/4885GSK3B 3553/4885DYRK1A 4538/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NFATC1 3976/4885GSK3B 3553/4885DYRK1A 4538/4885 |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | FGFR2, FGFR1, FGFR3 | NFATC1 1945/4885GSK3B 818/4885DYRK1A 677/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | NFATC1 3976/4885GSK3B 3553/4885DYRK1A 4538/4885 |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | NFATC1 2107/4885GSK3B 722/4885DYRK1A 1614/4885 |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | NFATC1 1885/4885GSK3B 756/4885DYRK1A 4430/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NFATC1 3976/4885GSK3B 3553/4885DYRK1A 4538/4885 |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | NFATC1 2107/4885GSK3B 722/4885DYRK1A 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.